Cytosine Arabinoside

DRUG12 trials

Sponsors

SWOG Cancer Research Network, Lymphoma Study Association, Johann Wolfgang Goethe University Hospital, Northern Italy Leukemia Group, PETHEMA Foundation

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaLangerhans Cell HistiocytosisLeukemiaLymphoid Blastic Phase of Chronic Myeloid LeukemiaLymphoma, Large-Cell, DiffusePhiladelphia Positive Acute Lymphoblastic Leukemia

Phase 1

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

CompletedNCT02891278

Columbia UniversityAcute Myeloid Leukemia

Start: 2016-08-11End: 2020-11-17Updated: 2023-04-12

Phase 2

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Johann Wolfgang Goethe University HospitalLymphoid Blastic Phase of Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia

Start: 2002-03-31Updated: 2007-10-19

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

RecruitingNCT02205762

North American Consortium for HistiocytosisLangerhans Cell Histiocytosis

Start: 2016-11-02End: 2026-07-31Target: 1400Updated: 2025-05-25

Phase 3

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

CompletedNCT00085709

SWOG Cancer Research NetworkLeukemia

Start: 2004-07-31End: 2014-08-31Updated: 2015-09-30

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

CompletedNCT00137995

Lymphoma Study AssociationLymphoma, Large-Cell, Diffuse

Start: 2003-06-30End: 2008-10-31Updated: 2019-08-28

A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)

CompletedNCT00495287

Northern Italy Leukemia GroupAcute Myelogenous Leukemia

Start: 2006-11-30End: 2015-12-31Updated: 2016-03-31

Phase 4

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

CompletedNCT00526305

PETHEMA FoundationAcute Lymphoblastic Leukemia

Start: 2000-01-31End: 2005-04-30Target: 100Updated: 2010-01-05

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

CompletedNCT00526409

PETHEMA FoundationAcute Lymphoblastic Leukemia

Start: 2005-06-30End: 2014-10-31Target: 40Updated: 2014-10-28

LAL-BR/2001: Study Treatment to Low Risk ALL

CompletedNCT00526175

PETHEMA FoundationAcute Lymphoblastic Leukemia

Start: 2001-06-30End: 2015-12-31Target: 150Updated: 2016-01-20

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

CompletedNCT00853008

PETHEMA FoundationAcute Lymphoblastic Leukemia

Start: 2003-01-31End: 2012-12-31Target: 100Updated: 2020-04-07

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

PETHEMA FoundationAcute Lymphoblastic Leukemia

Start: 2010-05-31End: 2022-12-31Target: 100Updated: 2022-01-19

Unknown Phase

Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)

CompletedNCT02101983

University of RochesterAcute Myeloid Leukemia

Start: 2011-05-31End: 2017-08-31Updated: 2018-06-27

Related Papers

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Haematologica2023-08-0327 citations

Characteristics and prognostic impact of<i>IDH</i>mutations in AML: a COG, SWOG, and ECOG analysis

Blood Advances2023-06-0250 citations

P+R‐ICE: PEMBROLIZUMAB IN COMBINATION WITH R‐ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ‐ ONGOING TRIAL

Hematological Oncology2023-06-01

Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis

Blood Advances2023-03-0845 citations

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

Blood Advances2022-01-1420 citations

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Blood2020-11-04

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

Haematologica2020-08-2722 citations

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial

Blood Advances2020-01-2415 citations

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Blood2019-11-131 citations

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

Cancers2019-09-2825 citations

PF182 CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL‐07FRAIL)

HemaSphere2019-06-01

PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS‐MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

HemaSphere2019-06-01

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML

Blood Advances2019-04-0431 citations

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Blood2018-11-29

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Blood2018-11-29

Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06

Blood2018-11-29

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Blood2018-04-0422 citations

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Blood2015-12-031 citations

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Blood2013-11-1514 citations

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Blood2013-11-159 citations

1 more papers not shown